title: Sublingual vaccination with fusion protein consisting of the functional domain of hemagglutinin A of Porphyromonas gingivalis and Escherichia coli maltose-binding protein elicits protective immunity in the oral cavity.
abstract: This study demonstrated that sublingual immunization with a fusion protein, 25k-hagA-MBP, which consists of a 25-kDa antigenic region of hemagglutinin A purified from Porphyromonas gingivalis fused to maltose-binding protein (MBP) originating from Escherichia coli as an adjuvant, elicited protective immune responses. Immunization with 25k-hagA-MBP induced high levels of antigen-specific serum IgG and IgA, as well as salivary IgA. High level titers of serum IgG and IgA were also induced for almost 1 year. In an IgG subclass analysis, sublingual immunization with 25k-hagA-MBP induced both IgG1 and IgG2b antibody responses. Additionally, numerous antigen-specific IgA antibody-forming cells were detected from the salivary gland 7 days after the final immunization. Mononuclear cells isolated from submandibular lymph nodes (SMLs) showed significant levels of proliferation upon restimulation with 25k-hagA-MBP. An analysis of cytokine responses showed that antigen-specific mononuclear cells isolated from SMLs produced significantly high levels of IL-4, IFN-γ, and TGF-β. These results indicate that sublingual immunization with 25k-hagA-MBP induces efficient protective immunity against P. gingivalis infection in the oral cavity via Th1-type and Th2-type cytokine production.
authors: Department of Oral Immunology, Nihon University School of Dentistry at Matsudo, Chiba, Japan.
authors: Satoshi
authors: S
authors: Yuzawa
authors: Tomoko
authors: T
authors: Kurita-Ochiai
authors: Tomomi
authors: T
authors: Hashizume
authors: Ryoki
authors: R
authors: Kobayashi
authors: Yoshimitsu
authors: Y
authors: Abiko
authors: Masafumi
authors: M
authors: Yamamoto
mesh_terms: D000286:Administration, Sublingual; D016301:Alveolar Bone Loss / Q000517:prevention & control; D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis; D001426:Bacterial Proteins / Q000276:immunology*; D001428:Bacterial Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D016866:Bacteroidaceae Infections / Q000517:prevention & control; D016207:Cytokines / Q000378:metabolism; D029968:Escherichia coli Proteins / Q000276:immunology; D005260:Female; D007070:Immunoglobulin A / Q000032:analysis; D037102:Lectins / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000276:immunology; D058619:Maltose-Binding Proteins / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009055:Mouth / Q000276:immunology*; D016966:Porphyromonas gingivalis / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000276:immunology*; D012463:Saliva / Q000737:chemistry / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D001428:Bacterial Vaccines; D016207:Cytokines; D029968:Escherichia coli Proteins; D007070:Immunoglobulin A; D037102:Lectins; D058619:Maltose-Binding Proteins; D011993:Recombinant Fusion Proteins; D014614:Vaccines, Synthetic; C114923:hemagglutinin A, Porphyromonas gingivalis